Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFOX + cediranib
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
FOLFOX + cediranib is a combination regimen consisting of the chemotherapy protocol FOLFOX (folinic acid [leucovorin], fluorouracil [5-FU], and oxaliplatin) plus the small molecule tyrosine kinase inhibitor cediranib. - **FOLFOX** is a standard chemotherapy regimen for colorectal cancer and other solid tumors. It works by combining agents that disrupt DNA synthesis (fluorouracil), enhance cytotoxicity (folinic acid), and cause DNA crosslinking leading to apoptosis (oxaliplatin). - **Cediranib** is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, blocking angiogenesis required for tumor growth. Cediranib also inhibits platelet-derived growth factor receptors and c-Kit. The addition of cediranib to FOLFOX aims to combine direct cytotoxic effects with antiangiogenic therapy for enhanced antitumor activity[3][6][10].
- Brand names
- RECENTIN
- Other names
- FOLFOXfolinic acid + fluorouracil + oxaliplatin + cediranibleucovorin calcium + 5-fluorouracil + oxaliplatin + cediranib
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on FOLFOX + cediranib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFOX + cediranib.